GH Research PLC
ghres.comWhat Do They Do?
Develops inhaled and intravenous mebufotenin drug candidates for patients with treatment-resistant depression and other psychiatric and neurological disorders.
20-F for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing…View ↗
Our portfolio currently includes GH001, our proprietary inhalable mebufotenin product candidate and GH002, our proprietary intravenous…View ↗
We are developing our mebufotenin product candidates, GH001 and GH002, in our focus area of psychiatric and neurological disorders.View ↗
How Do They Make Money?
No revenue reported yet.
20-F for FY2025, filed Mar 5, 2026
How Are They Changing?
Intranasal candidate
The earlier portfolio included an intranasal mebufotenin candidate in preclinical development; the latest portfolio description focuses on inhaled and intravenous candidates.
20-F for FY2022, filed Mar 9, 2023 20-F for FY2025, filed Mar 5, 2026
Who Do They Compete With?
Competes with Janssen, AtaiBeckley, Axsome Therapeutics, COMPASS Pathways, Helus Pharma, and Definium Therapeutics
20-F for FY2025, filed Mar 5, 2026Based on the current understanding of regulatory agencies, TRD encompasses patients who have not been helped by two or more MDD…View ↗
Loading...
